After Mizuho Securities and JMP Securities gave Concert Pharma (NASDAQ: CNCE) a Buy rating last month, the company received another Buy, this time from Berenberg Bank. Analyst Esther Hong maintained a Buy rating on Concert Pharma today and set a price target of $11.00. The company's shares closed last Wednesday at $2.80, close to its 52-week low of $2.57. According to TipRanks.com, Hong 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -30.2% and a 13.2% success rate. Hong covers the Healthcare sector, focusing on stocks such as Cerevel Therapeutics Holdings, ACADIA Pharmaceuticals, and Aldeyra Therapeutics.
https://www.tipranks.com/news/blurbs/concert-pharma-cnce-received-its-third-buy-in-a-row?utm_source=advfn.com&utm_medium=referral
Concert Pharmaceuticals (NASDAQ:CNCE)
Historical Stock Chart
From May 2022 to Jun 2022 Click Here for more Concert Pharmaceuticals Charts.
Concert Pharmaceuticals (NASDAQ:CNCE)
Historical Stock Chart
From Jun 2021 to Jun 2022 Click Here for more Concert Pharmaceuticals Charts.